Last reviewed · How we verify
NCT05255237: AA
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Phase 3 trial testing Jaktinib in Alopecia Areata in 315 participants. Completed in 28 June 2024.
28 June 2024
Quick facts
| Lead sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 315 |
| Start date | 25 March 2022 |
| Primary completion | 28 June 2024 |
| Estimated completion | 28 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Jaktinib — full drug profile →
Conditions studied
- Alopecia Areata — all drugs for Alopecia Areata →
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.
Ma T, Zhang T, Miao F, Liu J, et al · · 2025 · cited 13× · PMID 40260013 · DOI 10.1002/mco2.70182 -
Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I, Pikiewicz W, Kaminiów K. · · 2023 · cited 6× · PMID 38138551 · DOI 10.3390/molecules28248064
Verify or expand the search:
- PubMed search for NCT05255237
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Jaktinib
Trials testing the same drug.
- NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
- NCT04866056 — Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. · Phase 1, PHASE2 · terminated
- NCT05051761 — Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata · Phase 3 · completed
- NCT04612699 — A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis · Phase 2 · completed
- NCT04617028 — Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis · Phase 3 · completed
Other recruiting trials for Alopecia Areata
Currently open trials in the same condition.
- NCT07242638 — Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome · Phase 2 · recruiting
- NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
- NCT07205159 — A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. · Phase 1 · recruiting
- NCT06747611 — Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata · Phase 2 · recruiting
Other Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials
Trials by the same sponsor.
- NCT05279001 — A Safety and Tolerability Study of Jaktinib · Phase 1 · unknown
- NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
- NCT06132243 — Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions · Phase 1 · completed
- NCT05864573 — Study of ZGGS15 in Patients With Advanced Solid Tumors · Phase 1 · completed
- NCT05584800 — Study of ZGGS18 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05255237 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05255237.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing